Clinical Trials

Inclusion Criteria:

• Cohort A:
  • Received a minimum of 1 to a maximum of 3 prior lines of therapy including a proteasome inhibitor (PI) and immunomodulatory therapy (IMiD), and lenalidomide refractory per International Myeloma Working Group (IMWG) guidelines.
• Cohort B:
  • Received one line of prior therapy including a PI and an IMiD, and disease progression per IMWG criteria ≤ 12 months after treatment with autologous stem cell transplantation (ASCT) or ≤ 12 months from the start of anti-myeloma therapy for participants who have not had an ASCT.
• Cohort C:
  • Previously treated with a PI, an IMiD, an anti-CD38 monoclonal antibody and B-cell maturation antigen (BCMA)-directed therapy.
• Cohort D:
  • Newly diagnosed multiple myeloma per IMWG with a history of 4 to 8 total cycles of initial therapy, including induction, high-dose therapy, and ASCT with or without consolidation.
• Cohort E:
  • Have newly diagnosed multiple myeloma without prior therapy and classified as high risk per International Staging System (ISS) stage III criteria, defined as: beta 2 microglobulin greater than (>) 5.5 milligram per litre (mg/L).
• Cohort A, B, C, E:
  • Serum monoclonal paraprotein (M-protein) level ≥ 1.0 gram per deciliter (g/dL) or urine M-protein level ≥ 200 milligram (mg)/24 hours.
  • Light chain multiple myeloma in whom only measurable disease is by serum free light chain (FLC) levels in the serum: Serum immunoglobulin FLC ≥ 10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio.
• Cohort A, B, C:
  • For participants with neither serum nor urine measurable disease, baseline positron emission tomography/ computed tomography (PET/CT) or whole body magnetic resonance imaging (MRI) may be used to satisfy the measurable disease criteria.
• Cohort A, B, C, D, E:
  • Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1.

Exclusion Criteria:

• Cohort A, B, D:
  • Any therapy that is targeted to BCMA.
• Cohort A, B, C, D:
  • Prior treatment with chimeric antigen receptor T (CAR-T) therapy directed at any target.
  • Ongoing toxicity from previous anticancer therapy must resolve to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy.
  • Received a cumulative dose of corticosteroids equivalent to ≥ 70 mg of prednisone within the 7 days (Cohort A, B, C) or 14 days (Cohort D) prior to apheresis.
  • Serious underlying medical condition, such as:
    • Evidence of active viral or bacterial infection requiring systemic antimicrobial therapy, or uncontrolled systemic fungal infection.
    • Active autoimmune disease or a history of autoimmune disease within 3 years.
    • Overt clinical evidence of dementia or altered mental status.
    • Any history of Parkinson's disease or other neurodegenerative disorder.
• Cohort A, B, C, D, E:
  • Known active, or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma